Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005

Thorax

Volumn 52, Issue 4, 1997, Pages 348-354

  Hamilton, A L ^a   Watson, R M ^a   Wyile, G ^b   O'Byrne, P M ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b Miles Canada Inc   (Canada)

Author keywords

Allergens; Asthma; BAYx 1005; Leukotriene synthesis inhibition

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; ALLERGEN; ARACHIDONATE 5 LIPOXYGENASE; PLACEBO;

ADULT; ARTICLE; ASTHMA; BRONCHOSPASM; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION TEST; MALE; PRIORITY JOURNAL; PROVOCATION TEST;

EID: 0030996540     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.52.4.348     Document Type: Article

References (36)

1. O'Byrne PM, Dolovich J, Hargreave FE. State of the art: late asthmatic responses. Am Rev Respir Dis 1987;36: 740-51.
2. Cockcroft DW, Ruffin RE, Dolovich J, Hargreave FE. Allergen-induced increase in nonallergic bronchial reactivity. Clin Allergy 1977;7:503-13.
3. Cartier A, Thomson NC, Frith PA, Roberts R, Hargreave FE. Allergen-induced increase in bronchial responsiveness to histamine: relationship to the late asthmatic response and change in airway caliber. J Allergy Clin Immunol 1982; 70:170-7.
4. De Monchy JGR, Kauffman HF, Venge P, Koeter GH, Jansen HAI, Sluiter HJ, et al. Bronchoalveolar eosinophilia during allergen-induced late asthmatic reaction. Am Rev Respir Dis 1985;131:373-6.
5. Dahlen S-E, Hedqvist P, Hammarstrom S, Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature 1980;288:484-6.
6. Hanna CJ, Bach MK, Pare PD, Schellenberg RR. Slow-reacting substances (leukotrienes) contract human airway and pulmonary vascular smooth muscle in vitro. Nature 1981;343-4.
7. Barnes NC, Piper PJ, Costello JF. Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects. Thorax 1984;39:500-4.
8. Adelroth E, Morris MM, Hargreave FE, O'Byrne PM. Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls. N Engl J Med 1986;315:480-4.
9. 4 in normal and asthmatic subjects. Am Rev Respir Dis 1987;135:333-7.
10. Drazen JM, Austen KF. State of the art: leukotrienes and airway responses. Am Rev Respir Dis 1987;136:985-98.
11. 4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis 1990;142:112-9.
12. 4 levels during early and late asthmatic responses. J Allergy Clin Immunol 1990;86: 211-20.
13. 4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1989;i: 584-7.
14. Woodward DF, Wasserman MA, Weichmann BM. Investigation of leukotriene involvement in the vasopermeability response associated with guinea-pig tracheal anaphylaxis: comparison with cutaneous anaphylaxis. Eur J Pharmacol 1983;93:9-19.
15. Marom Z, Shelhamer JH, Bach MK, Morton DR, Kaliner M. Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982;126:449-51.
16. Taylor IK, O'Shaugnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204 219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991;337:690-4.
17. 4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol 1992;90:193-201.
18. Friedman BS, Bel EH, Buntinx A, Tanaka W, Han Y-HR, Shingo S, et al. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis 1993;147:839-44.
19. Diamant Z, Timmers MC, van der Veen H, Friedman BS, de Smet M, Depre M, et al. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol 1995;95:42-51.
20. Hatzelmann A, Fruchtmann R, Mohrs KH, Raddatz S, Muler-Peddinghaus R. Mode of action of the new selective leukotriene synthesis inhibitor BAYx 1005 [(R)-2-[4-(Quinolin-2-yl methoxy)phenyl]-2-cyclopentyl] acetic acid] and structurally related compounds. Biochem Pharmacol 1993;45:101-11.
21. Morris JF, Koski A, Johnson LC. Spirometric standards for healthy nonsmoking adults. Am Rev Respir Dis 1971;103: 57-67.
22. Cockcroft DW, Murdock KY, Kirby J, Hargreave FE. Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine. Am Rev Respir Dis 1987;135:264-7.
23. Cockcroft DW, Killian DN, Mellon JJA, Hargreave PK. Bronchial reactivity of inhaled histamine: a method and clinical survey. Clini Allergy 1977;7:235-43.
24. Hills M, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol 1979;8:7-20.
25. 4 and granulocytic infiltration into asthmatic airways. Lancet 1993;341:989-90.
26. 4 in subjects with mild asthma. Am J Respir Crit Care Med 1996;153: A290.
27. 4 on the airway responsiveness to histamine in subjects with asthma and normal subjects. J Allergy Clin Immunol 1988;82:654-60.
28. 4: comparison of potency in canine trachea in vivo. Prostaglandins 1983,25:237-43.
29. Henderson WR. The role of leukotrienes in inflammation. Ann Intern Med 1994;121:68-97.
30. Hui KP, Taylor IK, Taylor GW, Rubin P, Kesterson J, Barnes NC, et al. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991;46:184-9.
31. Nasser SM, Bell GS, Hawksworth RJ, Spruce KE, MacMillan R, Williams AJ, et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses. Thorax 1994;49:743-8.
32. Fruchtman R, Mohrs KH, Hatzelmann A, Raddatz S, Fugmann B, Junge B, et al. In vitro pharmacology of BAYx 1005, a new inhibitor of leukotriene synthesis. Agents Actions 1993;38:188-95.
33. Gorenne I, Labat C, Gascard JP, Norel X, Muller-Peddinghaus R, Mohrs KH, et al. (R)2-[4-(Quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl] acetic acid (BAYx 1005), a potent leukotriene synthesis inhibitor: effects on anti-IgE challenge in human airways. J Pharmacol Exp Ther 1994;268:868-72.
34. Muller-Peddinghaus R, Kohlsdorfer C, Theisen-Popp P, Fruchtman R, Perzborn E, Beckermann B, et al. BAYx 1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokmetics. J Pharmacol Exp Ther 1993;267:51-7.
35. Dahlén B, Kumlin M, Ihre E, Zetterstrom O, Dahlén S-E. Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005. Thorax 1997;52:342-7.
36. Inman MD, Watson R, O'Byrne PM. Reproducibility and utility of methacholme airway responsivenes in studies of allergen-induced asthma. Am J Respir Crit Care Med 1996, 153:A623.